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Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial
Infarction Receiving XIENCE V Everolimus-Eluting Stents: Four-Year Results
from the XIENCE V USA Study
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Background: XIENCE V USA is a prospective, multicenter, single-arm, FDA con-
dition- of-approval study to evaluate the safety and effectiveness of the XIENCE V
Everolimus Eluting Stent (XIENCE V, Abbott Vascular, Santa Clara, CA) in a real-
world, all-comer population. Clinical outcomes at 1 year in AMI patients have been
previously reported with low rates of target lesion revascularization (TLR), cardiac
death, MI and stent thrombosis (ST). Whether these early results from XIENCE V
USA in AMI are sustained long term has not been reported.
Methods: This study consecutively enrolled 5054 patients undergoing PCI with
XIENCE V only from July to December 2008. A total of 4176 patients who completed
4 year clinical follow up or experienced endpoint events were included in this anal-
ysis. Clinical outcomes in patients with (n¼667, 125 patients with STEMI) and
without (n¼3509) AMI were compared up to 4 years.
Results: Mean age, gender distribution, lesion length, and number of lesions and
vessels treated were similar across the two groups. The AMI group had a fewer di-
abetics, lower rates of dyslipidemia, hypertension, but higher rates of tobacco use,
unstable angina, prior MI, B2/C lesions, compared to the non-AMI group. Clinical
outcomes at 4 years are shown in the table.Table. Clinical outcomes through 4 years
AMI
(N ¼ 667)
(L ¼ 921)
Non-AMI
(N¼3509)
(L ¼ 4918) P-value
Cardiac Death 6.3% 4.9% 0.1585
MI (WHO deﬁnition) 6.9% 4.4% 0.0093
Q-MI 3.5% 1.2% 0.0003
NQMI 3.9% 3.2% 0.3208
Target Lesion Revascularization (TLR) 10.9% 10.4% 0.7189
Target Lesion Failure (TLF) 18.1% 15.3% 0.0897
Early ST (def./prob.) 0-30 days 0.76% 0.37% 0.1893
Late ST (def./prob.) 31-365 days 0.32% 0.51% 0.7555
Very late ST (def./prob.) 1-2 year 0.17% 0.13% 0.5624
Very late ST (def./prob.) 2-3 year 0.37% 0.13% 0.2268
Very late ST (def./prob.) 3-4 year 0.57% 0.20% 0.1402
Overall ST(def./prob.) 0-4 years 2.38% 1.44% 0.1333
TLF: composite of cardiac death, MI attributed to target vessel, and TLRConclusions: In this large, multicenter, real-world study, low clinical event rates at 1
year were sustained through 4 years. Although the rates of clinical outcomes in AMI
patients were slightly higher than those in non-AMI patients, the rates remained low in
both groups. A stent design that combines thin struts, a durable ﬂuoropolymer and
optimal drug dose likely underlies low long term event rates, even in thrombotic lesions.B12 JACC Vol 64/11/Suppl B jTCT-40
10 mg/L of high-sensitivity C-reactive protein on admission is a powerful
predictive marker in patients with ST-segment elevation myocardial infarction,
but not in patients with non-ST-segment elevation myocardial infarction
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Background: C-reactive protein is an important inﬂammatory marker even in acute
phase. Limited date are available whether high-sensitivity C-reactive protein (hs-CRP)
on admission predicts long-term clinical outcome depending on clinical presentation
deﬁned as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment
elevation myocardial infarction (NSTEMI).
Methods:Weenrolled consecutive 3,962 acutemyocardial infarction (AMI) patientswho
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnvergent
REgistry of cAtholic and chonnAm university for AMI) from January 2004 to December
2009.Theprimaryendpointwas a composite of all-causedeath, anymyocardial infarction,
and any revascularization. Cut-off level of initial hs-CRP was 10 mg/L.
Results: Median follow up duration was 38.3 months (interquartile range 22.8 to
55.9months). Elevated hs-CRP was observed in 1,439 patients (36.3%). The rate of
primary endpoint was higher in high hs-CRP group (37.5% vs. 25.8%; 540 events vs.
652 events, P< 0.001). In multivariable Cox proportional hazards regression, high hs-
CRP level is independent predictor of primary endpoint (hazard ratio (HR) 1.20, 95%
conﬁdence interval (CI) 1.06-1.36, P¼0.003). In subgroup analysis, higher hs-CRP
level is associated with long-term clinical outcome in STEMI, but not in NSTEMI
(HR 1.29, 95% CI 1.10-1.52, P¼0.002. vs. HR 1.13, 95% CI 0.94-1.37, P¼0.20;
Interaction P¼0.023).Conclusions: Hs-CRP level on admission over than 10 mg/L is independent predictor
for long-term clinical outcome in patients with STEMI, but not in patients with
NSTEMI.
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CAUSES OF MORTALITY AFTER PERCUTANEOUS CORONARY
INTERVENTION IN A LARGE REGIONAL CARDIAC CENTRE IN
CANADA
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Background: Mortality after percutaneous coronary intervention (PCI) is considered
as a surrogate marker for the quality of care in interventional cardiology. But mortality
after PCI may be related to multiple factors. We examine the frequencies and the
causes of mortality after PCI in the contemporary practice.
Methods: Royal Columbian Hospital is the tertiary regional cardiac centre of Fraser
Health Region in British Columbia that has a population of 1.9 million, and it provides
24/7 primary STEMI revascularization service for the region. Patients’ demographics
and procedural data are prospectively recorded in the provincial catheterization
database, which is linked to the vital statistics. The cause of death was reviewed
independently by 2 interventional cardiologists through chart review, and was clas-
siﬁed into 3 categories: (1) PCI-related, (2) non-PCI-related cardiac death, and (3)
non-cardiac death. Patients who died suddenly or out-of-the-hospital were all pre-
sumed to have PCI-related death due to stent thrombosis, unless proven otherwise.
Results: From 06/2011 to 12/2013, 6,041 PCI procedures were performed, and 1,847
(31%) cases were done during acute STEMI. A total of 154 (2.5%) patients diedSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
